Abstract:e13023 Background: Human epidermal growth factor receptor-2 (HER2) positive breast cancer is a growing concern due to the boom in anti-HER2 therapy. Trastuzumab as the most classic anti-HER2 therapy drug, combined with chemotherapy has become the standard first-line treatment for advanced HER2-positive (HER2+) patients. Although some real-world studies of trastuzumab have been reported, less is known about the role of hormone receptors (HR) in first-line combined therapy. For maintenance therapy after chemotherapy combined with anti-HER2 therapy, the guidance given by clinical trials is the maintenance of targeted therapy. However, for those with HER2+/HR-positive (HR+) breast cancer, whether adding endocrine maintenance therapy can benefit progression-free survival (PFS) in addition to anti-HER2 therapy still needs more research. Thus, the purpose of this study was to retrospectively analyze real-world data, determine the factors that influence the trastuzumab-based therapy in advanced HER2-positive breast cancer patients. Methods: We retrospectively collected the treatment information of advanced breast cancer patients underwent first-line chemotherapy with trastuzumab from 2012 to 2021 in Zhejiang Cancer Hospital. Kaplan–Meier analysis and Cox regression methods were used to calculate and compare the PFS. Results: The study finally enrolled 285 patients meeting the requirement, including 150 HER2+/HR-negative (HR-) and 135 HER2+/HR+ (triple-positive) patients. The median chemotherapy treatment cycles and trastuzumab cycles were 7 (6-8) and 12 (7-17) cycles, respectively. For triple-positive breast cancer, maintenance endocrine therapy was aslo given concurrently with trastusumab in 75 patients after chemotherapy and trastusumab. Overally, the median PFS of first-line treatment was 11.73 (10.16-13.30) months, which was consistent with literature reports. Multivariate analysis revealed that HR positive [hazard ratio, 0.69; 95% confidence interval (CI), 0.52–0.92; P = 0.010], and non-brain metastasis (hazard ratio, 0.54; 95% CI, 0.29–0.99; P = 0.048) were independent prognostic factors. Further Kaplan–Meier analysis demonstrated triple-positive patients with maintenance endocrine therapy significantly had longer PFS than triple-positive patients without maintenance endocrine therapy and HER2+/HR- patients (21.33m vs. 10.13m vs. 9.53m, respectively, P < 0.001). Conclusions: HR-positive was an independent prognostic factor for HER2-positive advanced breast cancer patients receiving first-line chemotherapy with trastuzumab. And endocrine therapy combined trastuzumab as Maintenance after chemotherapy prolonged PFS in HR-positive subgroup patients.

Hormone Receptor Status Predicts the Clinical Outcome of Human Epidermal Growth Factor 2-Positive Metastatic Breast Cancer Patients Receiving Trastuzumab Therapy: a Multicenter Retrospective Study.

EFFECT OF ADJUVANT ENDOCRINE THERAPY ON ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE AND HER2 NEGATIVE BREAST CANCER PATIENTS

Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2 (Her2)-Positive Early-Stage Breast Cancer: A Real-World Retrospective Study in Chinese Patients.

[Retrospective Analysis of Trastuzumab Treatment in 141 Patients with Her-2 Positive Breast Cancer].

A Retrospective Study on the Efficacy of Trastuzumab in HER2-Positive and Tamoxifen-Refractory Breast Cancer with Brain Metastasis

HER2-positive Patients Receiving Trastuzumab Treatment Have a Comparable Prognosis with HER2-negative Advanced Gastric Cancer Patients: a Prospective Cohort Observation.

Maintenance endocrine therapy prolonged progression-free survival of first-line chemotherapy with trastuzumab in advanced HR-positive, HER2-positive breast cancer patients.

Clinical Study of Therapy by Trastuzumab for Breast Cancer

Efficacy and Safety of Trastuzumab Combined with Chemotherapy for First-Line Treatment and Beyond Progression of HER2-overexpressing Advanced Breast Cancer.

Efficacy and Safety of Neoadjuvant Therapy for HER2-positive Early Breast Cancer: a Network Meta-Analysis

Late Stage Gastric Cancer Patients With Extra Gained Her2 Positivity By Dual Block Assessment May Not Show Compromised Efficacy To Trastuzumab Treatment

Effects of hormone receptor status on patient clinic and survival in HER2 positive breast cancer

Trastuzumab plus pertuzumab in combination with chemotherapy in metastatic HER2-positive breast cancer: a retrospective single-armed cohort study in China

Clinicopathological Characteristics, Evolution, and Treatment Outcomes of Hormone Receptor-Negative/her2-low Metastatic Breast Cancer: a Pooled Analysis of Individual Patient Data from Three Prospective Clinical Trials

For or Against Adjuvant Trastuzumab for Pt1a-Bn0m0 Breast Cancer Patients with HER2-positive Tumors: a Meta-Analysis of Published Literatures.

[Chinese HER2 Positive Early Breast Cancer Trastuzumab Adjuvant Therapy: Preliminary Outcomes].

Trastuzumab in the Adjuvant Treatment of HER2-positive Early Breast Cancer Patients: a Meta-Analysis of Published Randomized Controlled Trials.

Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer:A meta-analysis of randomized controlled trials

Effect of Trastuzumab among HER2-Positive Breast Cancer Patients That Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy

Genomic Alterations Correlated to Trastuzumab Resistance and Clinical Outcomes in HER2+/HR- Breast Cancers of Patients Living in Northwestern China

Efficacy and safety of trastuzumab retreatment beyond progression in HER2 positive metastatic breast cancer